

SUSPECT ADVERSE REACTION REPORT											

I. REACTION INFORMATION

1. INITIALS	1a. COUNTRY	2. DATE OF BIRTH			2a. AGE	3. SEX	4-6. REACTION ONSET			8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION <input type="checkbox"/> PATIENT DIED <input type="checkbox"/> LIFE THREATENING <input type="checkbox"/> HOSPITALIZATION <input type="checkbox"/> DISABILITY OR INCAPACITY <input type="checkbox"/> CONGENITAL ANOMALY/BIRTH DEFECT <input type="checkbox"/> OTHER MEDICALLY IMPORTANT CONDITION <input type="checkbox"/> REQUIRED INTERVENTION (MEDICAL DEVICE)		
PRIVACY	PA	Day	Month	Year	56 Year(s)	F	Day	Month	Year			
23											Apr	2025
7+13 DESCRIBE REACTION(S) (including relevant tests/lab data) Event Verbatim [Low Level Term] itchy throat [Throat irritation] (10043521 v28.0) - Not serious - Unknown - 23-Apr-2025/UNK burning sensation sensation in her mouth and lips [Oral discomfort] (10030973 v28.0) - Not serious - Unknown - 23-Apr-2025/UNK cystitis [Cystitis] (10011781 v27.1) - Not serious - Unknown - 26-Apr-2025/UNK Truxima, Solution for injection (Rituximab) [Incorrect product formulation administered] (10074946 v28.0) - Not serious - Unknown -												

II. SUSPECT DRUG(S) INFORMATION

14. SUSPECT DRUG(S) (include generic name) #1 [Suspect] Truxima, Solution for injection (Rituximab)				20. DID REACTION ABATE AFTER STOPPING DRUG? <input type="checkbox"/> YES <input type="checkbox"/> NO <input type="checkbox"/> NA			
15. DAILY DOSE(S) #1 500 milligram				16. ROUTE(S) OF ADMINISTRATION #1 Intravesical			
17. INDICATION(S) FOR USE #1 Drug use for unknown indication [Drug use for unknown indication] (10057097 v27.1)				21. DID REACTION REAPPEAR AFTER REINTRODUCTION ? <input type="checkbox"/> YES <input type="checkbox"/> NO <input type="checkbox"/> NA			
18. THERAPY DATES (from/to) #1 23-Apr-2025				19. THERAPY DURATION #1			

III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUGS(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction)	
23. OTHER RELEVANT HISTORY (e.g. diagnostics, allergics, pregnancy with last month of period, etc.) From / To Dates Description # 1	

IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER LABORATORIOS STEIN Escazú, Meridiano Building, 5th floor 10203 San José CR		26. REMARKS	
	24b. MFR CONTROL NO. 2025000199	25b. NAME AND ADDRESS OF REPORTER PRIVACY	
24c. DATE RECEIVED BY MANUFACTURER 30-Apr-2025	24d. REPORT SOURCE <input type="checkbox"/> STUDY <input type="checkbox"/> LITERATURE <input type="checkbox"/> AUTHORITY <input type="checkbox"/> HEALTH PROFESSIONAL <input checked="" type="checkbox"/> OTHER		
DATE OF THIS REPORT 14-May-2025	25a. REPORT TYPE <input checked="" type="checkbox"/> INITIAL <input type="checkbox"/> FOLLOW UP :		

7+13. DESCRIBE REACTION(S) continued

Case description : This initial non-serious spontaneous report was received from a consumer (patient) and non-health professional in Panama on 30 Apr 2025.

This case refers to a 56-year-old female patient who experienced events itchy throat, burning sensation in her mouth and lips, and cystitis following therapy with Truxima (Rituximab).
The patient received Truxima (Rituximab) at 500 milligram with unspecified frequency for unknown indication on 23 Apr 2025. Batch/lot number was unknown.
The patient experienced events itchy throat and burning sensation in her mouth and lips (coded to Itchy throat, Oral discomfort) on 23 Apr 2025 and cystitis (coded to Cystitis) on 26 Apr 2025. Corrective treatment in response to Itchy throat and Oral discomfort were chlorotrimetron and corticosteroids while unknown for Cystitis. Action taken with Truxima was withdrawn (temporarily). Dechallenge result and outcome of events were unknown.
Relevant medical history and concomitant medication were not reported.
Past drug included Methotrexate at unknown dose via unknown route on unknown therapy start date until 2024 (withdrawn) (reaction: Cystitis).
Additionally, event Inappropriate formulation of drug administered was captured considering Truxima, Solution for injection (Rituximab) was used which is not an established formulation per RSI. The reporter did not describe this event.
The reporter assessed the events as non-serious, whereas causality with Truxima was related.

Case Comment: Case comment: Causality of Oral discomfort (unlisted, non-serious), Throat irritation, Cystitis (both listed, non-serious) is related based on the established temporal relationship between events' occurrence and drug use. Causality of event Incorrect product formulation administered (unlisted, non-serious) is not applicable and dependent on the HCP's prescribing practice.
Duplicate numbers : 2025PA013564 (Celltrion).

14-19. Drugs

#	Name	Dosage Information	Lot/Batch	Route of Admin.	Indication	Therapy dates	Therapy duration
1	[Suspect] Truxima Solution for injection (Rituximab)	500 milligram	UNK	Intravesical	Drug use for unknown indication [Drug use for unknown indication] (10057097 v27.1)	23-Apr-2025	

23. OTHER RELEVANT HISTORY continued

Past Drug Therapy

1 methotrexate

Indication : Drug use for unknown indication

Reaction : Cystitis

23. OTHER RELEVANT HISTORY continued

Methotrexate (METHOTREXATE); Drug Indication: Drug use for unknown indication (Product used for unknown indication), Drug Reaction: Cystitis (Cystitis)